Proposed Issue of Equity and Grant of Options
30 June 2026
Physiomics plc
("Physiomics" or the "Company")
Proposed Issue of Equity and Grant of Options
Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, announces the conditional issue of new ordinary shares of 0.40 pence each in Physiomics (the "Ordinary Shares") in respect of the board of directors of Physiomics' (the "Board" or the "Directors") remuneration policy as announced on 8 May 2026, whereby each Director is remunerated partially through the issue of new Ordinary Shares.
Nick Tulloch, Chairman, will receive 4,000,000 new Ordinary Shares, representing remuneration of £20,000. Mike Whitlow, Executive Director, and Ian Bagnall, Finance Director, will each receive 5,000,000 new Ordinary Shares, representing remuneration of £25,000. All of the new Ordinary Shares are to be issued at a price of 0.50 pence per new Ordinary Share, being the closing price on 28 April 2026, the day before the Directors joined the Board. It is intended that awards of Ordinary Shares to Directors will be made once in each financial year in respect of part of their remuneration.
As the Company currently has no headroom to issue new Ordinary Shares, the above share awards to the Directors will be made following the Company's next annual general meeting ("AGM") at which resolutions will be proposed to grant authorities for the issue of the new Ordinary Shares and the Options described below.
Physiomics further announces the grant of options ("Options") to Directors for a total of 20,139,858 Ordinary Shares.
Each Option provides the holder with the right to receive one new Ordinary Share on its exercise. 10,909,089 of the Options were granted with an exercise price of 0.55 pence per new Ordinary Share and 9,230,769 of the Options were granted with an exercise price of 0.65 pence per new Ordinary Share, representing a premium of approximately 15 per cent. and approximately 35 per cent. respectively to the mid-market closing price of 0.48 pence per Ordinary Share on 26 June 2026.
The Options in aggregate will represent 4.3 per cent of the Company's share capital, ceteris paribus, as enlarged by the issue of the New Ordinary Shares above. The Options will expire on the fifth anniversary of the date of grant if not exercised.
These option awards reflect the Board's policy to conserve the Company's cash resources and accept a significant part of their remuneration as equity in the Company. The Board further considers that these awards of Options offer significant incentive and alignment with shareholders as a whole in relation to Physiomics' future success, for which the Board believes the Company is well positioned, supported by its robust operational progress and strategic developmental activities.
The Options form part of a new share option scheme and the Company intends to consider option awards on an annual basis in the future. Furthermore, it is the Company's intention to grant further options on the same terms to Physiomics employees.
The following awards have been made:
Name
Title
Options exercisable at 0.55p
Options exercisable at 0.65p
Nick Tulloch
Chairman
3,636,363
3,076,923
Mike Whitlow
Executive Director
3,636,363
3,076,923
Ian Bagnall
Finance Director
3,636,363
3,076,923
PDMR dealings
Pursuant to the arrangements set out above, a total of 14,000,000 new Ordinary Shares will be issued by the Company. Following this issuance, the total numbers of Ordinary Shares that will be held following Admission (as defined below) by the Directors, as Persons Discharging Managerial Responsibility ("PDMRs") of the Company as at the date of this announcement, are as follows:
Name
New Ordinary Shares to be issued
Total Ordinary Shares held in the Company following Admission
As a percentage of the Company's enlarged issued ordinary share capital following Admission
Options held in the Company
Nick Tulloch
4,000,000
4,000,000
0.86%
6,713,286
Mike Whitlow
5,000,000
61,000,000
13.06%
6,713,286
Ian Bagnall
5,000,000
20,000,000
4.28%
6,713,286
Total
14,000,000
The FCA notification in respect of these PDMR dealings and grant of Options, made in accordance with the requirements of the UK Market Abuse Regulation, is appended further below.
Admission
Application will be made for 14,000,000 new Ordinary Shares to be admitted to trading on AIM following the AGM as described above and subject to shareholder approval ("Admission").
ENDS
For more information about Physiomics and its services, please visit www.physiomics.co.uk.
Enquiries:
Physiomics plc
Mike Whitlow
Email: info@physiomics.co.uk
Strand Hanson Ltd (NOMAD and Broker)
James Dance & James Bellman
Tel: +44 (0) 20 7409 3494
About Physiomics
Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting- edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 140 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Name
Position
Nick Tulloch
Chairman
Mike Whitlow
Executive Director
Ian Bagnall
Finance Director
2
Reason for the notification
a)
Position/status
See above
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Physiomics plc
b)
LEI
213800A71DSZ6ABMTQ91
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 0.40p each in Physiomics plc
Identification code (ISIN) for Physiomics plc ordinary shares: GB00BDR6W943
b)
Nature of the transaction
Issue of new Ordinary Shares as remuneration
c)
Price(s) and volume(s)
Name
Price(s)
Volume(s)
Nick Tulloch
0.50 pence
4,000,000
Mike Whitlow
0.50 pence
5,000,000
Ian Bagnall
0.50 pence
5,000,000
d)
Aggregated information:
- Aggregated volume
- Price
N/A
e)
Date of the transaction
29 June 2026
f)
Place of the transaction
Outside a trading venue
1
Details of the person discharging managerial responsibilities / person closely associated
a)
Name
Name
Position
Nick Tulloch
Chairman
Mike Whitlow
Executive Director
Ian Bagnall
Finance Director
2
Reason for the notification
a)
Position/status
See above
b)
Initial notification /Amendment
Initial notification
3
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
Physiomics plc
b)
LEI
213800A71DSZ6ABMTQ91
4
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)
Description of the financial instrument, type of instrument
Identification code
Ordinary shares of 0.40p each in Physiomics plc
Identification code (ISIN) for Physiomics plc ordinary shares: GB00BDR6W943
b)
Nature of the transaction
Grant of options over new Ordinary Shares
c)
Price(s) and volume(s)
Name
Price(s)
Volume(s)
Nick Tulloch
0.55 pence
3,636,363
Mike Whitlow
0.55 pence
3,636,363
Ian Bagnall
0.55 pence
3,636,363
Nick Tulloch
0.65 pence
3,076,923
Mike Whitlow
0.65 pence
3,076,923
Ian Bagnall
0.65 pence
3,076,923
d)
Aggregated information:
- Aggregated volume
- Price
N/A
e)
Date of the transaction
29 June 2026
f)
Place of the transaction
Outside a trading venue
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDIOEEAEKNASLKEAA
